| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/20/2011 | EP2345653A1 Morphinan compounds |
| 07/20/2011 | EP2345650A1 Amorphous (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole as anti-ulcer agent |
| 07/20/2011 | EP2345649A1 Benzimidazole compound in crystal form and salt thereof |
| 07/20/2011 | EP2345646A1 Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions |
| 07/20/2011 | EP2345644A1 Indazole compound |
| 07/20/2011 | EP2345643A1 New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof |
| 07/20/2011 | EP2345642A1 Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents |
| 07/20/2011 | EP2345641A1 New secondary 8-hydroxyquinoline-7-carboxamide derivatives |
| 07/20/2011 | EP2345640A1 Adamantyl- acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| 07/20/2011 | EP2345639A1 Cyclic hydroxylamine derivatives, their preparation and use as antioxidants |
| 07/20/2011 | EP2345637A2 3, 10, and 12a substituted tetracycline compounds |
| 07/20/2011 | EP2345636A1 Casr agonist |
| 07/20/2011 | EP2345635A1 Amino acid derivative |
| 07/20/2011 | EP2345629A1 Fluorene compound and use thereof for medical purposes |
| 07/20/2011 | EP2345455A1 Lacosamide for the treatment of hyperexcitability disorder and diseases associated with sodium channel dysfunction |
| 07/20/2011 | EP2345427A1 Fluoran complex |
| 07/20/2011 | EP2345426A1 Composite organic compound powder for medical use, method for producing same and suspension of same |
| 07/20/2011 | EP2345418A1 Milk fat for the treatment of mucositis |
| 07/20/2011 | EP2345416A1 Pharmaceutical composition for purifing vein and preparation method thereof |
| 07/20/2011 | EP2345415A1 Therapeutic/prophylactic agent for prostate cancer |
| 07/20/2011 | EP2345414A1 Tacrolimus preparation for external applications |
| 07/20/2011 | EP2345413A2 Composition and use of a long-acting oral bioadhesive endoparasiticide gel based on doramectin |
| 07/20/2011 | EP2345412A1 Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| 07/20/2011 | EP2345411A1 Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
| 07/20/2011 | EP2345410A1 Controlled release pharmaceutical composition |
| 07/20/2011 | EP2345409A1 Therapeutic agent for adult t-cell leukemia |
| 07/20/2011 | EP2345408A2 Acid labile drug formulations |
| 07/20/2011 | EP2345407A1 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| 07/20/2011 | EP2345406A1 Use of dimer diol in the production of bodily fluid substitutes |
| 07/20/2011 | EP2344639A2 Compositions and methods for inhibiting expression of transthyretin |
| 07/20/2011 | EP2344638A1 Compositions and methods for inhibiting expression of an rna from west nile virus |
| 07/20/2011 | EP2344637A1 Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna |
| 07/20/2011 | EP2344547A1 Polysaccharides containing carboxyl functional groups substituted by a hydrophobic alcohol derivative |
| 07/20/2011 | EP2344514A2 Synthetic methods and derivatives of triphosphate oligonucleotides |
| 07/20/2011 | EP2344512A1 Platinum complex with antitumor activity |
| 07/20/2011 | EP2344505A2 Indole and indoline derivatives and methods of use thereof |
| 07/20/2011 | EP2344504A1 Pyrrolotriazine kinase inhibitors |
| 07/20/2011 | EP2344503A2 5-azaindole bisphosphonates |
| 07/20/2011 | EP2344502A2 Pyrimidinyl pyridone inhibitors of jnk |
| 07/20/2011 | EP2344501A1 Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
| 07/20/2011 | EP2344500A1 Novel combinations of antibacterial nitrogenous heterocyclic compounds with other antibacterial compounds, and use thereof as drugs |
| 07/20/2011 | EP2344499A1 Novel nitrogenous heterocyclic compounds, preparation thereof and use thereof as antibacterial medicaments |
| 07/20/2011 | EP2344497A1 Azaindole derivatives as crth2 receptor antagonists |
| 07/20/2011 | EP2344496A1 Amides of diazabicyclooctanes and uses thereof |
| 07/20/2011 | EP2344495A1 Tricyclic oxazolidinone antibiotic compounds |
| 07/20/2011 | EP2344494A1 Aminotriazolopyridines and their use as kinase inhibitors |
| 07/20/2011 | EP2344493A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 07/20/2011 | EP2344492A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 07/20/2011 | EP2344490A2 4-morpholino-pyrido[3,2-d]pyrimidines active on pi3k |
| 07/20/2011 | EP2344487A1 Hepatitis c inhibitor compounds |
| 07/20/2011 | EP2344486A2 Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof |
| 07/20/2011 | EP2344485A2 Oxazolidinyl antibiotics |
| 07/20/2011 | EP2344484A1 S1p receptors modulators and their use thereof |
| 07/20/2011 | EP2344483A1 Compounds which have activity at m1 receptor and their uses in medicine |
| 07/20/2011 | EP2344482A1 Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors |
| 07/20/2011 | EP2344481A2 Viral and fungal inhibitors |
| 07/20/2011 | EP2344480A1 Fused heteroaryl diamide compounds useful as mmp-13 inhibitors |
| 07/20/2011 | EP2344479A2 1,2-benzisothiazolinone and isoindolinone derivatives |
| 07/20/2011 | EP2344477A1 Small molecule bradykinin b2 receptor modulators |
| 07/20/2011 | EP2344476A2 Tricyclic carbamate jak inhibitors |
| 07/20/2011 | EP2344475A1 Quinazolinone, quinolone and related analogs as sirtuin modulators |
| 07/20/2011 | EP2344474A1 Picolinamide derivatives as kinase inhibitors |
| 07/20/2011 | EP2344473A1 Heterocyclic pim-kinase inhibitors |
| 07/20/2011 | EP2344472A1 Isoquinolinone derivatives |
| 07/20/2011 | EP2344471A1 7-piperidinoalkyl-3,4-dihydroquinolone derivative |
| 07/20/2011 | EP2344470A1 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| 07/20/2011 | EP2344466A1 2-ethoxy benzoic acid derivative |
| 07/20/2011 | EP2344465A1 Crystalline forms of (r) -5- [3-chloro-4-( 2, 3-dihydroxy-propoxy)-benz [z]ylidene]-2- [z]-propylimino) -3-0-tolyl-thiazolidin-4-one |
| 07/20/2011 | EP2344463A2 1,2 -thiazol yl derivatives as cannabinoid receptor ligands |
| 07/20/2011 | EP2344461A1 Salts of isobutyric acid (1 r*, 2r*, 4r* ) -2- (2-{ [3- (4, 7-dimeth0xy-1 h-benzoimidazol-2-yl) -propyl]-methyl-amino } -ethyl) -5-phenyl-bicyclo [2.2.2]oct-5- en- 2 -yl |
| 07/20/2011 | EP2344460A1 Novel imidazolidine compounds as androgen receptor modulators |
| 07/20/2011 | EP2344459A1 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases |
| 07/20/2011 | EP2344458A1 Heteroaryls amide derivatives and their use as glucokinase activators |
| 07/20/2011 | EP2344457A1 Substituted spiroamines |
| 07/20/2011 | EP2344456A1 Novel potassium channel blocker |
| 07/20/2011 | EP2344454A1 Antioxidant compounds and methods of their use |
| 07/20/2011 | EP2344453A2 Activators of human pyruvate kinase |
| 07/20/2011 | EP2344452A1 Selective glycosidase inhibitors and uses thereof |
| 07/20/2011 | EP2344451A2 Sulfur-linked compounds for treating opthalmic diseases and disorders |
| 07/20/2011 | EP2344449A1 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use |
| 07/20/2011 | EP2344447A2 Gaba conjugates and methods of use thereof |
| 07/20/2011 | EP2344446A1 S1p receptors modulators |
| 07/20/2011 | EP2344442A1 Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids and preparation thereof |
| 07/20/2011 | EP2344441A2 14-hydroxy-docosahexaenoic acid compounds |
| 07/20/2011 | EP2344253A1 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes |
| 07/20/2011 | EP2344204A2 Telomerase inhibitors and methods of use thereof |
| 07/20/2011 | EP2344198A2 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof |
| 07/20/2011 | EP2344197A1 Lactose and cellulose-based tableting aid |
| 07/20/2011 | EP2344176A1 Use of bradykinin b1 receptor antagonists in intestinal fibrosis treatment |
| 07/20/2011 | EP2344170A1 Antimicrobial compositions |
| 07/20/2011 | EP2344168A1 Anti-infective formulation and methods of use |
| 07/20/2011 | EP2344167A2 Inhibitors of f18+ e. coli binding |
| 07/20/2011 | EP2344166A1 Pharmaceutical composition for the treatment of gastrointestinal irritation disorders |
| 07/20/2011 | EP2344165A2 Pharmaceutical compositions comprising boronic acid compounds |
| 07/20/2011 | EP2344164A1 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| 07/20/2011 | EP2344163A1 Oral formulation |
| 07/20/2011 | EP2344162A2 5ht7 receptor ligands and compositions comprising the same |
| 07/20/2011 | EP2344161A1 Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
| 07/20/2011 | EP2344160A1 Tryptophan hydroxylase inhibitors and methods of their use |
| 07/20/2011 | EP2344159A1 Medicaments and methods for inhibition of scarring |